Senzime (SEZI) Q3 2025 earnings summary

Executive summary

• Achieved 80% revenue growth in constant currencies for Jan–Sep 2025, with sensor deliveries up 78% year-over-year and strong expansion in the U.S. and Europe.

• Net sales for Jan–Sep 2025 reached SEK 75.7 million, up 70% year-over-year, driven by strong U.S. performance, new hospital contracts, and increased utilization of TetraGraph systems and disposable sensors.

• EBITDA improved by 20% year-to-date, with a loss reduction of SEK 15.9 million over nine months.

• Secured major contracts with leading U.S. hospital systems and the U.S. Department of Defense.

• Strategic deals, regulatory approvals in Mexico and Japan, and new software launches enhanced market position.

Financial highlights

• Net sales in Q3 reached SEK 26.5 million; Jan–Sep total SEK 75.7 million, up 70% year-over-year.

• Gross margin before depreciation for Q3 was 61.2%, and Jan–Sep was 62.9%, impacted by tariffs and currency effects.

• EBITDA improved by 20% to -63.8 MSEK YTD; Q3 EBITDA improved by 8% to -19.4 MSEK.

• Cash and cash equivalents at end of Q3: SEK 106.6 million.

• Earnings per share for Jan–Sep: SEK -0.66 (improved from -0.77 YoY).

Outlook and guidance

• Confident in delivering within the full-year 2025 sales range in constant currencies, despite currency headwinds.

• Price adjustments in the U.S. and potential production relocation are planned to mitigate tariff impacts.

• Continued focus on profitable growth, recurring revenues, and cost discipline.